Global Inhaled Nitric Oxide Delivery Systems Market Size to worth USD 537.1 Million by 2033: Market Insight Report

Global Inhaled Nitric Oxide Delivery Systems Market Size to worth USD 537.1 Million by 2033

According to a research report published by Spherical Insights & Consulting, the Global Inhaled Nitric Oxide Delivery Systems Market Size is Expected to Grow from USD 344.5 Million in 2023 to USD 537.1 Million by 2033, at a CAGR of 4.54% during the forecast period 2023-2033. 

Browse key industry insights spread across 210 pages with 110 Market data tables and figures & charts from the report on the Global Inhaled Nitric Oxide Delivery Systems Market Size, Share, and COVID-19 Impact Analysis, By Type (Pediatric and Adult), By Application (HRF and AHRF), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.          

Inhaled nitric oxide delivery systems are medical devices intended to administer nitric oxide gas to patients in controlled dosages for therapeutic purposes. Nitric oxide is a vasodilator and is mainly used in the treatment of pulmonary hypertension, especially in neonatal and pediatric populations. These systems ensure precise delivery of inhaled nitric oxide, which helps to relax and dilate blood vessels in the lungs, improving oxygenation and reducing the need for mechanical ventilation. Inhaled nitric oxide therapy is widely used in critical care settings, including intensive care units (ICUs), and during surgeries involving cardiopulmonary bypass. Furthermore, the growth of the inhaled nitric oxide delivery systems market is driven by the increasing prevalence of respiratory and cardiovascular diseases, particularly pulmonary hypertension and acute respiratory distress syndrome (ARDS). The rising demand for effective and targeted therapies, especially in neonatal and pediatric intensive care, further propels the market. Also, advancements in technology have facilitated greater efficiency and safety measures of delivery systems for iNO that further increased hospital and clinics embracing their products on a high scale. Increasing popularity due to knowledge of better therapeutic value through iNO treatment supports market growth. However, the high cost of iNO therapy, including both the devices and the nitric oxide gas, may limit market growth, particularly in resource-constrained regions.

The pediatric segment is predicted to hold the greatest market share through the forecast period.

Based on the type, the inhaled nitric oxide delivery systems market is classified into pediatric and adult. Among these, the pediatric segment is predicted to hold the greatest market share through the forecast period. This is largely because there is a high incidence of pulmonary hypertension and other complications within the respiratory system, mainly in neonates and infants, mostly premature and critically ill infants. The use of inhaled nitric oxide has become widely adopted within neonatal intensive care units to treat issues like persistent pulmonary hypertension of the newborn, along with various respiratory disorders that improve oxygenation and decrease the rate of mechanical ventilation.

The AHRF segment is anticipated to hold the greatest market share during the projected timeframe.    

Based on the application, the inhaled nitric oxide delivery systems market is divided into HRF and AHRF. Among these, the AHRF segment is anticipated to hold the greatest market share during the projected timeframe. This is due to the widespread use of inhaled nitric oxide in the treatment of AHRF, particularly in critical care settings such as intensive care units (ICUs) and emergency departments. AHRF, which is characterized by severe oxygenation impairment, often requires immediate and effective intervention to improve oxygenation and reduce the risk of further complications.

North America is estimated to hold the largest inhaled nitric oxide delivery systems market share over the forecast period.

North America is estimated to hold the largest inhaled nitric oxide delivery systems market share over the forecast period. This market is largely driven by the U.S. and enjoys a very advanced healthcare infrastructure, large healthcare expenditure, and significant research and development activities. The presence of leading medical device manufacturers and a well-developed regulatory framework also helps in the growth of this market.

Asia-Pacific is predicted to have the fastest CAGR growth in the inhaled nitric oxide delivery systems market over the forecast period. This is driven by several factors, including the increasing prevalence of respiratory diseases, rising healthcare expenditure, and improving healthcare infrastructure in emerging economies such as China and India. Additionally, the growing focus on healthcare access and quality in these countries is likely to boost the adoption of advanced medical treatments and technologies, further propelling the market's expansion in the region.

Competitive Analysis

Major key players in the inhaled nitric oxide delivery systems market are Mallinckrodt Pharmaceuticals, Getinge AB, VERO Biotech, Linde plc, Beyond Air, Inc., SLE Ltd., Bellerophon Therapeutics, Air Liquide Healthcare, Circassia Pharmaceuticals, and International Biomedical.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In December 2023, Mallinckrodt plc announced that the U.S. FDA granted clearance for its INOmax EVOLVE DS delivery system, which is designed to deliver INOmax (nitric oxide) gas for inhalation. This system offers a specialized injector module that tracks gas delivery waveforms and ensures synchronized, proportional dosing of NO. The system is compatible with a range of ventilators and respiratory care devices that have been validated for use with the INOmax EVOLVE DS.

Market Segment

This study forecasts global, regional, and country revenue from 2023 to 2033. Spherical Insights has segmented the inhaled nitric oxide delivery systems market based on the below-mentioned segments:

Global Inhaled Nitric Oxide Delivery Systems Market, By Type

• Pediatric
• Adult

Global Inhaled Nitric Oxide Delivery Systems Market, By Application

• HRF
• AHRF

Global Inhaled Nitric Oxide Delivery Systems Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa